Accelerated Biomarker Discovery

Back to all technologies
Download as PDF
2017-COOK-67619
Conventionally screening and analysis of small molecules in heterogeneous samples is done through mass spectrometry (MS). Unfortunately, this process can be selective and time consuming when including sample preparation and data acquisition. In the case of obtaining molecular structural information, higher resolution MS of selected ions, or univariate analysis, must be performed to evaluate each metabolite individually. However, multivariate statistical methods could allow a broader comparison of samples and the molecular relationships.

Researchers at Purdue University have developed a tandem mass spectrometry method that allows complex samples to be rapidly analyzed for particular subgroups using a set of multiple reaction monitoring (MRM) transitions. This method aims to rapidly recognize chemical similarities in the samples through transitions that can be selected without prior knowledge of the compounds. MRM acts as a means of accelerated biomarker discovery, applicable to proteomics, lipidomics, metabolomics, etc. This strategy was applied to cerebrospinal fluid (CSF) to help identify biomarkers for Parkinson's disease. No specific biomarker was identified, but further improvements could show results and apply to other biomarker screenings and chemical profiling.

Advantages:
-Accelerated
-Identifies biomarkers
-Multivariate

Potential Applications:
-Biomarker screenings
-Chemical profiling
-Drug screenings
-Identify Parkinson's disease biomarker
Jul 14, 2017
Utility Patent
United States
10,168,312
Jan 1, 2019

Jul 22, 2016
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org